Song et al. developed an mGM‐CSF‐loaded, liver cancer cell‐based vaccine that potently activated dendritic cells and elicited tumour‐specific T cell responses. Mechanistically, radiation‐induced oxidative damage to mitochondrial DNA in cancer cells triggers the cGAS‐STING pathway in DCs, which synergizes with mGM‐CSF‐driven JAK2‐STAT3 signalling to ...
Zhiruo Song +15 more
wiley +1 more source
Pharmacological Inhibition of SP1 Reverses Cancer Stemness and Enhances Sorafenib Efficacy in Hepatocellular Carcinoma. [PDF]
Padelli M +7 more
europepmc +1 more source
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis. [PDF]
Peck-Radosavljevic M +17 more
europepmc +1 more source
Lysine l‐Lactylation: Bridging Metabolism, Chromatin and Disease
Enzymatic regulation of KL‐la. The enzymatic regulation of KL‐la involves two distinct pathways for L‐lactate accumulation: intracellular production through glycolysis‐derived pyruvate conversion by lactate dehydrogenase (LDH) or direct cellular uptake via monocarboxylate transporters (MCTs). These L‐lactate pools fuel two distinct lactylation pathways—
Anoosha Malik +10 more
wiley +1 more source
Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation. [PDF]
Kong L +16 more
europepmc +1 more source
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori +17 more
wiley +1 more source
C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma. [PDF]
Pang C +5 more
europepmc +1 more source
Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah +2 more
wiley +1 more source
AURKA suppresses NCOA4-mediated ferritinophagy to enhance sorafenib resistance in hepatocellular carcinoma. [PDF]
Zhu W +11 more
europepmc +1 more source
Five Advances in the Last 50 Years: Liver Malignancies
World Journal of Surgery, Volume 50, Issue 8, Page 2116-2120, August 2026.
Alex B. Blair, Timothy M. Pawlik
wiley +1 more source

